Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46)

Answers are grounded in this paper and cite their sources.

• What was the primary endpoint, and how big was the effect?
• What are the main limitations?
• How does this compare with earlier trials?